JP2024543253A5 - - Google Patents
Info
- Publication number
- JP2024543253A5 JP2024543253A5 JP2024527624A JP2024527624A JP2024543253A5 JP 2024543253 A5 JP2024543253 A5 JP 2024543253A5 JP 2024527624 A JP2024527624 A JP 2024527624A JP 2024527624 A JP2024527624 A JP 2024527624A JP 2024543253 A5 JP2024543253 A5 JP 2024543253A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- gene therapy
- polynucleotide
- seq
- transgene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163278905P | 2021-11-12 | 2021-11-12 | |
| US63/278,905 | 2021-11-12 | ||
| PCT/US2022/079756 WO2023086966A1 (en) | 2021-11-12 | 2022-11-11 | Materials and methods for slc6a1 gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543253A JP2024543253A (ja) | 2024-11-20 |
| JP2024543253A5 true JP2024543253A5 (https=) | 2025-10-27 |
Family
ID=86336739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527624A Pending JP2024543253A (ja) | 2021-11-12 | 2022-11-11 | Ｓｌｃ６ａ１遺伝子治療のための材料及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250002939A1 (https=) |
| EP (1) | EP4429715A4 (https=) |
| JP (1) | JP2024543253A (https=) |
| AU (1) | AU2022386664A1 (https=) |
| CA (1) | CA3238030A1 (https=) |
| WO (1) | WO2023086966A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024305531A1 (en) * | 2023-06-13 | 2026-01-22 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of neurofibromin 1 mutations and diseases resulting therefrom |
| WO2025228976A1 (en) * | 2024-04-29 | 2025-11-06 | UCB Biopharma SRL | Gene therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820380B2 (en) * | 2004-05-07 | 2010-10-26 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis |
| US12077772B2 (en) * | 2019-11-08 | 2024-09-03 | The Board Of Regents Of The University Of Texas System | Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A1 |
-
2022
- 2022-11-11 AU AU2022386664A patent/AU2022386664A1/en active Pending
- 2022-11-11 CA CA3238030A patent/CA3238030A1/en active Pending
- 2022-11-11 EP EP22893893.2A patent/EP4429715A4/en active Pending
- 2022-11-11 WO PCT/US2022/079756 patent/WO2023086966A1/en not_active Ceased
- 2022-11-11 JP JP2024527624A patent/JP2024543253A/ja active Pending
- 2022-11-11 US US18/708,777 patent/US20250002939A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535749A5 (https=) | ||
| JP2022508182A5 (https=) | ||
| JP2021106619A5 (https=) | ||
| RU2017115477A (ru) | Полинуклеотиды aadc для лечения болезни паркинсона | |
| JP2022551986A5 (https=) | ||
| JP2021003120A5 (https=) | ||
| RU2018116076A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
| JP2020533959A5 (https=) | ||
| JP2023537980A5 (https=) | ||
| JP2013531471A5 (https=) | ||
| JP2024099770A5 (https=) | ||
| JP2024543253A5 (https=) | ||
| JP2020519629A5 (https=) | ||
| JP2021525245A5 (https=) | ||
| JP2019537576A5 (https=) | ||
| JP2022524434A5 (https=) | ||
| CA3158518A1 (en) | Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases | |
| JP2017529395A5 (https=) | ||
| JP2022525302A5 (https=) | ||
| JP2022551744A5 (https=) | ||
| JP2023537358A5 (https=) | ||
| FI3373980T3 (fi) | Menetelmiä lihasdystrofian hoitamiseksi | |
| JP2023059858A5 (https=) | ||
| JP2023524024A5 (https=) | ||
| JP2023520763A5 (https=) |